ARWR Valuation

Arrowhead Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

39.230

-0.37(-0.934%)1D

ARWR Relative Valuation

ARWR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARWR is overvalued; if below, it's undervalued.

Historical Valuation

Arrowhead Pharmaceuticals Inc (ARWR) is now in the Fair zone, suggesting that its current forward PS ratio of 39.60 is considered Fairly compared with the five-year average of -27.61. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between 24.62 to 46.30 according to relative valuation methord.

Relative Value

Fair Zone

24.62-46.30

Current Price：38.02

Fair

-19.16

Trailing

Forward

-21.32

EV/EBITDA

Arrowhead Pharmaceuticals Inc. (ARWR) has a current EV/EBITDA of -21.32. The 5-year average EV/EBITDA is -30.78. The thresholds are as follows: Strongly Undervalued below -102.57, Undervalued between -102.57 and -66.67, Fairly Valued between 5.12 and -66.67, Overvalued between 5.12 and 41.02, and Strongly Overvalued above 41.02. The current Forward EV/EBITDA of -21.32 falls within the Historic Trend Line -Fairly Valued range.

-21.08

EV/EBIT

Arrowhead Pharmaceuticals Inc. (ARWR) has a current EV/EBIT of -21.08. The 5-year average EV/EBIT is -24.70. The thresholds are as follows: Strongly Undervalued below -78.55, Undervalued between -78.55 and -51.62, Fairly Valued between 2.23 and -51.62, Overvalued between 2.23 and 29.16, and Strongly Overvalued above 29.16. The current Forward EV/EBIT of -21.08 falls within the Historic Trend Line -Fairly Valued range.

39.23

Arrowhead Pharmaceuticals Inc. (ARWR) has a current PS of 39.23. The 5-year average PS is 25.29. The thresholds are as follows: Strongly Undervalued below -2.94, Undervalued between -2.94 and 11.17, Fairly Valued between 39.40 and 11.17, Overvalued between 39.40 and 53.51, and Strongly Overvalued above 53.51. The current Forward PS of 39.23 falls within the Historic Trend Line -Fairly Valued range.

-55.28

P/OCF

Arrowhead Pharmaceuticals Inc. (ARWR) has a current P/OCF of -55.28. The 5-year average P/OCF is -23.60. The thresholds are as follows: Strongly Undervalued below -156.77, Undervalued between -156.77 and -90.19, Fairly Valued between 42.98 and -90.19, Overvalued between 42.98 and 109.57, and Strongly Overvalued above 109.57. The current Forward P/OCF of -55.28 falls within the Historic Trend Line -Fairly Valued range.

-47.39

P/FCF

Arrowhead Pharmaceuticals Inc. (ARWR) has a current P/FCF of -47.39. The 5-year average P/FCF is 2.71. The thresholds are as follows: Strongly Undervalued below -53.45, Undervalued between -53.45 and -25.37, Fairly Valued between 30.80 and -25.37, Overvalued between 30.80 and 58.88, and Strongly Overvalued above 58.88. The current Forward P/FCF of -47.39 falls within the Undervalued range.

Arrowhead Pharmaceuticals Inc (ARWR) has a current Price-to-Book (P/B) ratio of 10.47. Compared to its 3-year average P/B ratio of 11.69 , the current P/B ratio is approximately -10.37% higher. Relative to its 5-year average P/B ratio of 12.67, the current P/B ratio is about -17.35% higher. Arrowhead Pharmaceuticals Inc (ARWR) has a Forward Free Cash Flow (FCF) yield of approximately -0.00%. Compared to its 3-year average FCF yield of -12.14%, the current FCF yield is approximately -99.97% lower. Relative to its 5-year average FCF yield of -7.26% , the current FCF yield is about -99.96% lower.

10.38

P/B

Median3y

11.69

Median5y

12.67

-0.00

FCF Yield

Median3y

-12.14

Median5y

-7.26

Competitors Valuation Multiple

The average P/S ratio for ARWR's competitors is 71.73, providing a benchmark for relative valuation. Arrowhead Pharmaceuticals Inc Corp (ARWR) exhibits a P/S ratio of 39.23, which is -45.31% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ARWR.O

Arrowhead Pharmaceuticals Inc

CRISPR Therapeutics AG

Telix Pharmaceuticals Ltd

Performance Decomposition

Market capitalization of ARWR increased by 50.71% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 27.77M.

The secondary factor is the Margin Expansion, contributed -94.76%to the performance.

Overall, the performance of ARWR in the past 1 year is driven by Revenue Growth. Which is more sustainable.

NaN%

0.00 → 27.77M

Revenue Growth

-94.76%

-12.29K → -643.40

Margin Expansion

NaN%

0.00 → -34.46

P/E Change

50.71%